-
Mashup Score: 28
Florida’s Department of Health is led by state Surgeon General Joe Ladapo, an outspoken skeptic of the Covid-19 vaccine.
Source: POLITICOCategories: Infectious Disease, Latest HeadlinesTweet-
This is stupid and dangerous. It is one thing to leave decisions of #vaccination to families but it’s another thing to give families NO OPTION to make that choice. I’m pretty speechless regarding this idiotic move by #publichealth leaders in #FL https://t.co/Z0ZOR8fb5W
-
-
Mashup Score: 1Mosunetuzumab receives European Commission approval for the treatment of relapsed or refractory follicular lymphoma - 2 year(s) ago
On June 8, 2022, it was announced that the European Commission (EC) has granted approval for the use of mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received ≥2 lines of systemic therapy.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEWS 🚨 Mosunetuzumab granted EC approval for the treatment of R/R follicular lymphoma #mednews #lymsm #fl https://t.co/Kpvzq9oZwp
-
-
Mashup Score: 1European Commission Approves Mosunetuzumab for Patients with R/R Follicular Lymphoma - 2 year(s) ago
The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The European Commission has granted a conditional marketing authorization to #mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies. #FL #lymsm https://t.co/PdMXxcUeYg
-
-
Mashup Score: 1Zanubrutinib Plus Obinutuzumab Elicits Improved Responses in Relapsed/Refractory Follicular Lymphoma - 2 year(s) ago
The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival. #FL #lymsm #ASCO22 https://t.co/vON6pJeONW
-
-
Mashup Score: 1
Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Findings from an arm of the EPCORE NHL-2 trial, presented at #ASCO22, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide. #lymsm #FL https://t.co/mBq1KrldhQ
-
-
Mashup Score: 0Tisagenlecleucel receives FDA approval for the treatment of relapsed or refractory follicular lymphoma - 2 year(s) ago
On May 28, 2022, it was announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for the use of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product, for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received ≥2 lines of systemic therapy.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 N E W S 🚨 Tisagenlecleucel granted @US_FDA approval for the treatment of relapsed or refractory follicular #lymphoma in adult patients 👉 https://t.co/EGoK4CTfXn 👈 #FL #lymsm https://t.co/NSYVo8XxYM
-
-
Mashup Score: 3Treatment patterns and survival outcomes in patients with R/R follicular lymphoma: a multicenter cohort study - 2 year(s) ago
This large cohort study showed that patients with R/R FL received heterogenous treatments in the third-line setting or later, with differences in therapy-specific overall responses. Although there were high response rates to novel therapies, these were short-lived.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🩺 Heterogeneity in the treatment pattern and outcomes in patients with R/R follicular #lymphoma 🤓 Read more and take our quick quiz! 👉 https://t.co/k85xBHpRrU 👈 #lymsm #FL
-
-
Mashup Score: 1
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Elizabeth Budde, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What results have you seen with mosunetuzumab in patients with high-risk follicular lymphoma (FL)?
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
👀 Have you seen this? During #ASH2021, the #LymphomaHub spoke with @elizabeth_budde, @cityofhope. We asked, What results have you seen with mosunetuzumab in patients with high-risk #FL? 👉 https://t.co/0uVVdeLUlw 👈 #lymsm #lymphoma
-
-
Mashup Score: 1Tisagenlecleucel receives EC approval for the treatment of relapsed or refractory follicular lymphoma - 2 year(s) ago
This is the third indication tisagenlecleucel has been approved for in the EU and the first CAR T-cell therapy approved for the treatment of FL, including patients with Grade 1, 2, and 3A relapsed or refractory FL.1 The approval is based on key data obtained from the phase II ELARA trial (NCT03568461), previously reported on the Lymphoma Hub.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 N E W S 🚨 Tisagenlecleucel granted EC approval for the treatment of R/R follicular #lymphoma. 📚Read more here 👉 https://t.co/nmugOqrA0z 👈 #fl #lymsm https://t.co/j8dEwPDEcf
-
-
Mashup Score: 1Risk of transformation to aggressive B-cell lymphoma in patients with primary refractory FL - 2 year(s) ago
Patients with primary refractory follicular lymphoma (FL) are known to have an unfavorable prognosis, with a very different clinical course compared with patients with FL, including exhibiting a higher risk of histological transformation (HT) to an aggressive lymphoma.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚 Bank Holiday Read 🔎 Are patients with primary refractory #FL at higher risk of transformation to aggressive B-cell #lymphoma? Find out more here: 👉 https://t.co/H9FqahPFM8 👈 #lymsm
-
I get the importance of decrying FL's decision not to pre-order (or recommend) #COVID19 vaccines for kids. But let's not scare parents by implying they'll have ZERO options. Vaccines will be available through pharmacies and providers' offices. https://t.co/x25UVzVgKG https://t.co/NAq5pqbv9s